Elbit Imaging Ltd (EMITF)

[midastouch017]

Signed a memorandum of understanding to invest $ 30 million Gamida

http://www.sponser.co.il/Article.aspx?ArticleId=78018&From=morearticles
(Goog Translate)

The company owned by Elbit Medical and CBI signed a non-binding memorandum of understanding with an investment fund at a value of $ 120 million against preference shares, options, etc.
08/03/2017 |8:57 |A sponsor |4 Add a comment | Print Article |
Want to trade cheaply through the bank?
Elbit Medical Technologies and Clal Biotechnology TASE announced that yesterday (Tuesday) announced Gamida them, held them at a rate of approximately 25% and 18%, respectively, that was signed with an investment fund for a non-binding memorandum of understanding to invest Gamida.
According to the MOU, will lead to investment fund investment of $ 30 million, along with other investors, based Gamida value of $ 120 million, before money. In return the said investment, the investors will receive preferred stock and warrants to purchase preferred shares of Gamida and other rights, including the protection of certain anti-dilution.
Recall that the CBI announced earlier this week that an agreement with the pharmaceutical company Teva acquisition of all holdings of nature (approximately -5.02% fully diluted) in Gamida, including all rights attaching to them. Following the acquisition of the shares of the acquired company will increase its stake to about Gamida 24%. According to the agreements between the parties, the value of the acquired shares is approximately $ 6 million, reflecting a company value of $ 120 million Gamida. acquired shares, the Company will issue shares of the Company to nature.
and and / or that the investment will be recruited additional investors and / or that the investment is completed. Gamida began CBI Elbit stressed as of this morning, there is no certainty that it will sign an investment agreement Final to experiment III Phase in patients with blood cancer and cancer lymph nodes. At the same time conducting Gamida Tests II Phase malignant blood diseases such as sickle cell anemia and thalassemia. the main drug of Gamida cell, NiCord, has been recognized by the FDA as an orphan drug and a treatment breakthrough.